WEBULL
News
HOTH
0.9400
-1.05%
-0.0100
BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog​, Ecolab
Reuters · 1d ago
BUZZ-Hoth Therapeutics rises as early obesity‑drug data in mice shows promise
Reuters · 1d ago
Hoth Therapeutics Says GDNF Beats Semaglutide In Preclinical Obesity, Liver Disease Study New Data
NASDAQ · 1d ago
Hoth Therapeutics Reports GDNF Outperforms Semaglutide in Preclinical Obesity Study
Reuters · 1d ago
HOTH THERAPEUTICS ANNOUNCES GROUNDBREAKING POSITIVE RESULTS: HOTH'S HT-VA GDNF SURPASSES SEMAGLUTIDE IN WEIGHT LOSS, GLUCOSE CONTROL, AND LIVER HEALTH IN OBESITY MODEL
Reuters · 1d ago
HOTH THERAPEUTICS INC - GDNF ATTENUATES WEIGHT GAIN BY 10-15% LEADING TO A PLATEAU IN THE FINAL WEEKS OF TREATMENT
Reuters · 1d ago
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study
Benzinga · 1d ago
EXCLUSIVE: Hoth Therapeutics Highlights HT/VA GDNF Data; Says In Head-To-Head Comparison Drug Demonstrated 'Superior Efficacy' Compared With Semaglutide Across Key Metrics
Benzinga · 1d ago
Weekly Report: what happened at HOTH last week (0202-0206)?
Weekly Report · 2d ago
Hoth Therapeutics confirms it holds no cryptocurrency assets
TipRanks · 6d ago
Hoth Therapeutics Confirms It Holds No Cryptocurrency Assets
Reuters · 6d ago
HOTH THERAPEUTICS ADDRESSES MARKET RUMOR, HOTH HOLDS NO CRYPTO CURRENCY ASSETS
Reuters · 6d ago
Weekly Report: what happened at HOTH last week (0126-0130)?
Weekly Report · 02/02 09:25
Weekly Report: what happened at HOTH last week (0119-0123)?
Weekly Report · 01/26 09:25
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half
Benzinga · 01/22 17:47
Hoth Therapeutics’ HT-001 shows 100% response in EFGR-treated cancer patients
TipRanks · 01/22 13:27
Hoth Therapeutics Announced Interim Results From The Open-Label Pharmacokinetic Cohort Of Its Ongoing CLEER-001 Clinical Trial Evaluating HT-001 In Cancer Patients Receiving EGFR Inhibitor Therapy; Primary Endpoint ARIGA Improved By ~50% From Baseline By Week 6, With All Evaluable Patients Reaching Low-severity Disease; Additional Endpoints Demonstrated ~34% Improvement In Oncology Toxicity And ~37% Reduction In Patient-Reported Pruritus
Benzinga · 01/22 13:16
Hoth Therapeutics Reports 100% Clinical Response in HT-001 Trial for EGFR-Treated Cancer Patients
Reuters · 01/22 13:13
HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY
Reuters · 01/22 13:13
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/21 21:05
More
Webull provides a variety of real-time HOTH stock news. You can receive the latest news about Hoth Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HOTH
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).